Resource Summary Report

Generated by FDI Lab - SciCrunch.org on Apr 1, 2025

PC-3

RRID:CVCL_0035
Type: Cell Line

Proper Citation

(RRID:CVCL_0035)

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0035

Proper Citation: (RRID:CVCL_0035)

Sex: Male

Defining Citation: PMID:447482, PMID:571045, PMID:1873816, PMID:3335022, PMID:3518877, PMID:6244232, PMID:8104329, PMID:8687134, PMID:9018337, PMID:9460501, PMID:9823299, PMID:10700174, PMID:10702678, PMID:10754530, PMID:10972993, PMID:11135431, PMID:11172901, PMID:11304728, PMID:11414198, PMID:11416159, PMID:12606952, PMID:12725112, PMID:14518029, PMID:15486987, PMID:15748285, PMID:17088437, PMID:17254797, PMID:17440963, PMID:19372543, PMID:20164919, PMID:21432867, PMID:22068913, PMID:22275356, PMID:22336246, PMID:22347499, PMID:22384151, PMID:22460905, PMID:22628656, PMID:23671654, PMID:23856246, PMID:23933261, PMID:24279929, PMID:24504141, PMID:24670534, PMID:25485619, PMID:25877200, PMID:25960936, PMID:26256267, PMID:26589293, PMID:26972028, PMID:27141528, PMID:27377824, PMID:27397505, PMID:27807467, PMID:28196595, PMID:29194687, PMID:30244336, PMID:30787054, PMID:30894373, PMID:31068700, PMID:31404090, PMID:31978347, PMID:32968452, PMID:35839778

Comments: Caution: There seem to be two distinct cell lines which were assigned NCBI_Iran catalog number C427., Omics: Transcriptome analysis by RNAseq., Omics: Transcriptome analysis by microarray., Omics: SNP array analysis., Omics: Secretome proteome analysis., Omics: Protein expression by reverse-phase protein arrays., Omics: Metabolome analysis., Omics: lncRNA expression profiling., Omics: GPI-anchored proteins analysis by proteomics., Omics: Glycoproteome analysis by proteomics., Omics: Fluorescence phenotype profiling., Omics: DNA methylation analysis., Omics: Deep quantitative proteome analysis., Omics: Deep proteome analysis., Omics: Deep exome analysis., Omics: Deep antibody staining analysis., Omics: CNV analysis., Omics: Array-based CGH., Population: Caucasian., Part of: NCI-60 cancer cell line panel., Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982)., Part of: MD

Anderson Cell Lines Project., Part of: JFCR39 cancer cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Name: PC-3

Synonyms: PC3, PC.3

Cross References: BTO:BTO_0001061, CLO:CLO_0008395, CLO:CLO_0051535, EFO:EFO_0002074, MCCL:MCC:0000380, CLDB:cl3881, CLDB:cl3883, Abcam:ab275472, AddexBio:C0019002/61, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:CRL-1435, ATCC:CRL-7934, BCRC:60122, BCRJ:0269, BioGRID_ORCS_Cell_line:193, BioSample:SAMN01821588, BioSample:SAMN01821653, BioSample:SAMN01821713, BioSample:SAMN03472063, BioSample:SAMN05292438, BioSample:SAMN10988356, cancercelllines:CVCL_0035, CCRID:1101HUM-PUMC000115, CCRID:3101HUMSCSP532, CCRID:3101HUMTCHu158, CCRID:4201HUM-CCTCC00095, CCTCC:GDC0095, Cell_Model_Passport:SIDM00088, ChEMBL-Cells:CHEMBL3307570, ChEMBL-Targets:CHEMBL390, CLS:300312, Cosmic:688118, Cosmic:704849, Cosmic:713868, Cosmic:719680, Cosmic:721366, Cosmic:721556, Cosmic:755297, Cosmic:759894, Cosmic:801350, Cosmic:809225, Cosmic:850414, Cosmic:869157, Cosmic:873002, Cosmic:875892, Cosmic:876396, Cosmic:897455, Cosmic:905934, Cosmic:911997, Cosmic:918502, Cosmic:920968, Cosmic:921048, Cosmic:922551, Cosmic:923957, Cosmic:943175, Cosmic:948379, Cosmic:949249, Cosmic:974299, Cosmic:1028650, Cosmic:1028702, Cosmic:1071477, Cosmic:1075273, Cosmic:1092627, Cosmic:1172628, Cosmic:1175888, Cosmic:1188436, Cosmic:1212489, Cosmic:1219448, Cosmic:1305380, Cosmic:1312367, Cosmic:1330910, Cosmic:1436048, Cosmic:1689714, Cosmic:1995613, Cosmic:1998469, Cosmic:2301588, Cosmic:2580130, Cosmic:2585153, Cosmic:2585230, Cosmic:2621167, Cosmic:2651772, Cosmic:2669172, Cosmic:2674178, Cosmic-CLP:905934, DepMap:ACH-000090, DSMZ:ACC-465, DSMZCellDive:ACC-465, ECACC:90112714, EGA:EGAS00001000610, EGA:EGAS00001000978, ENCODE:ENCBS420VDY, ENCODE:ENCBS451OVM, ENCODE:ENCBS504WVV, ENCODE:ENCBS596CTT, ENCODE:ENCBS608AAA, ENCODE:ENCBS609AAA, FCS-free:16-2-16-3-6-4, GDSC:905934, GEO:GSM2171, GEO:GSM50225, GEO:GSM50289, GEO:GSM91930, GEO:GSM142459, GEO:GSM142460, GEO:GSM482670, GEO:GSM525804, GEO:GSM595615, GEO:GSM648823, GEO:GSM743480, GEO:GSM750835, GEO:GSM784792, GEO:GSM799370, GEO:GSM799433, GEO:GSM847110, GEO:GSM844675, GEO:GSM844674, GEO:GSM887506, GEO:GSM888588, GEO:GSM1153442, GEO:GSM1178542, GEO:GSM1178543, GEO:GSM1181274, GEO:GSM1181303, GEO:GSM1374817, GEO:GSM1374818, GEO:GSM1670339, GEO:GSM2124647, GEO:GSM4962583, GEO:GSM4962584, GEO:GSM4962585, GEO:GSM4962586, GEO:GSM4962587, GEO:GSM4962588, GEO:GSM4962589, GEO:GSM4962590, GEO:GSM4962591, IARC_TP53:752, IARC_TP53:21276, ICLC:HTL97018, IZSLER:BS TCL 175, JCRB:JCRB9110, KCB:KCB 200725YJ, KCLB:21435, LiGeA:CCLE_525, LINCS_HMS:50454, LINCS_LDP:LCL-1299,

Lonza:125, MeSH:D000078722, NCBI_Iran:C427, NCI-DTP:PC-3, PharmacoDB:PC3_1248_2019, PRIDE:PRD000228, PRIDE:PRD000597, PRIDE:PXD000661, PRIDE:PXD002107, PRIDE:PXD003105, PRIDE:PXD005940, PRIDE:PXD005942, PRIDE:PXD005946, PRIDE:PXD008184, PRIDE:PXD030304, PRIDE:PXD032264, Progenetix:CVCL_0035, PubChem_Cell_line:CVCL_0035, RCB:RCB2145, SKY/M-FISH/CGH:2799, TKG:TKG 0600, TOKU-E:2868, Ubigene:YC-C010, Wikidata:Q7118483

ID: CVCL_0035

Record Creation Time: 20250131T202232+0000

Record Last Update: 20250131T204057+0000

Ratings and Alerts

No rating or validation information has been found for PC-3.

Warning: Discontinued: ATCC; CRL-7934
Caution: There seem to be two distinct cell lines which were assigned NCBI_Iran catalog number C427., Omics: Transcriptome analysis by RNAseq., Omics: Transcriptome analysis by microarray., Omics: SNP array analysis., Omics: Secretome proteome analysis., Omics: Protein expression by reverse-phase protein arrays., Omics: Metabolome analysis., Omics: lncRNA expression profiling., Omics: GPI-anchored proteins analysis by proteomics., Omics: Glycoproteome analysis by proteomics., Omics: Fluorescence phenotype profiling., Omics: DNA methylation analysis., Omics: Deep quantitative proteome analysis., Omics: Deep proteome analysis., Omics: Deep exome analysis., Omics: Deep antibody staining analysis., Omics: CNV analysis., Omics: Array-based CGH., Population: Caucasian., Part of: NCI-60 cancer cell line panel., Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982)., Part of: MD Anderson Cell Lines Project., Part of: JFCR39 cancer cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Data and Source Information

Source: Cellosaurus

Usage and Citation Metrics

We found 4165 mentions in open access literature.

Listed below are recent publications. The full list is available at FDI Lab - SciCrunch.org.

Champagne J, et al. (2025) Adoptive T cell therapy targeting an inducible and broadly shared product of aberrant mRNA translation. Immunity, 58(1), 247.

Sugawara T, et al. (2024) Dual targeting of the androgen receptor and PI3K/AKT/mTOR pathways in prostate cancer models improves antitumor efficacy and promotes cell apoptosis. Molecular oncology, 18(3), 726.

He J, et al. (2024) PTEN-mediated dephosphorylation of 53BP1 confers cellular resistance to DNA damage in cancer cells. Molecular oncology, 18(3), 580.

Graham MK, et al. (2024) The TERT Promoter is Polycomb-Repressed in Neuroblastoma Cells with Long Telomeres. Cancer research communications, 4(6), 1533.

Olotu O, et al. (2024) Germline-specific RNA helicase DDX4 forms cytoplasmic granules in cancer cells and promotes tumor growth. Cell reports, 43(7), 114430.

Sen A, et al. (2024) Assessments of prostate cancer cell functions highlight differences between a pan-PI3K/mTOR inhibitor, gedatolisib, and single-node inhibitors of the PI3K/AKT/mTOR pathway. Molecular oncology.

Pilié PG, et al. (2024) Ataxia-Telangiectasia Mutated Loss-of-Function Displays Variant and Tissue-Specific Differences across Tumor Types. Clinical cancer research : an official journal of the American Association for Cancer Research, 30(10), 2121.

Torres-Ayuso P, et al. (2024) PIM1 targeted degradation prevents the emergence of chemoresistance in prostate cancer. Cell chemical biology, 31(2), 326.

Lee KY, et al. (2024) Detection of Extracellular Vesicle-Derived RNA as Potential Prostate Cancer Biomarkers: Role of Cancer-type SLCO1B3 and ABCC3. Journal of Cancer, 15(3), 615.

Manzar N, et al. (2024) An integrative proteomics approach identifies tyrosine kinase KIT as a therapeutic target for SPINK1-positive prostate cancer. iScience, 27(3), 108794.

Van Espen B, et al. (2024) RNF185 Control of COL3A1 Expression Limits Prostate Cancer Migration and Metastatic Potential. Molecular cancer research : MCR, 22(1), 41.

Muñoz-Moreno L, et al. (2024) Antagonist of Growth Hormone-Releasing Hormone Receptor MIA-690 Suppresses the Growth of Androgen-Independent Prostate Cancers. International journal of molecular sciences, 25(20).

Wilkinson EJ, et al. (2024) WNT5A is a putative epi-driver of prostate cancer metastasis to the bone. Cancer medicine, 13(16), e70122.

Scott NR, et al. (2024) Mechanosensitive nuclear uptake of chemotherapy. Science advances, 10(51), eadr5947.

Tawfik I, et al. (2024) Breast cancer cells utilize T3 to trigger proliferation through cellular Ca2+ modulation. Cell communication and signaling : CCS, 22(1), 533.

Boulton DP, et al. (2024) MIRO2 promotes cancer invasion and metastasis via MYO9B

suppression of RhoA activity. Cell reports, 44(1), 115120.

Schofield JH, et al. (2024) Acod1 expression in cancer cells promotes immune evasion through the generation of inhibitory peptides. Cell reports, 43(4), 113984.

Beatson EL, et al. (2024) Genomic Characterization of Preclinical Prostate Cancer Cell Line Models. International journal of molecular sciences, 25(11).

Ruiz de Porras V, et al. (2024) Dual inhibition of MEK and PI3K?/?-a potential therapeutic strategy in PTEN-wild-type docetaxel-resistant metastatic prostate cancer. Frontiers in pharmacology, 15, 1331648.

He T, et al. (2024) Serine/threonine kinase 36 induced epithelial-mesenchymal transition promotes docetaxel resistance in prostate cancer. Scientific reports, 14(1), 729.